Menu
Back to Journals » Clinical Interventions in Aging » Volume 4
Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias
Authors Thomas S, Grossberg G
Published 28 September 2009 Volume 2009:4 Pages 367—377
DOI https://doi.org/10.2147/CIA.S6666
Review by Single anonymous peer review
Peer reviewer comments 3
Stuart J Thomas, George T Grossberg
Department of Neurology and Psychiatry, Saint Louis University School of Medicine, St. Louis, MO, USA
Abstract: Memantine is an uncompetitive N-methyl-D-aspartate receptor antagonist with moderate affinity. Its mechanism of action is neuroprotective and potentially therapeutic in several neuropsychiatric diseases. It has been approved by the FDA for the treatment of moderate to severe Alzheimer’s disease (AD) either as a monotherapy or in combination with cholinesterase inhibitors. This review covers key studies of memantine’s safety and efficacy in treating moderate to severe AD. It also covers current research into other dementias including but not exclusively mild AD and vascular dementia. Other studies on the efficacy of memantine for other neuropsychiatric diseases are discussed. Memantine is a safe and effective drug that merits further research on several topics. Clinicians should be aware of new studies and potential uses of memantine because of its safety and efficacy.
Keywords: memantine, Alzheimer’s disease, dementia
© 2009 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.